Community post

A phase II clinical trial for a phage lysin has been deemed successful! An anti-Staphylococcus aureus phage lysin, called exebacase, was just found to be both safe and effective at treating MRSA in patients. Exebacase is being developed by ContraFect using technology licensed from Rockefeller University.